What Does an EUS-RFA System Cost?

Capital and consumable pricing for endoscopic ultrasound-guided radiofrequency ablation systems remains largely unpublished. Here is what procurement officers can verify today — and what to demand from vendors.

Obtaining a firm price for an EUS-RFA system is genuinely difficult: the only FDA-cleared platform in the U.S. market does not publish list prices, GSA pricing does not appear in federal schedules for this specific configuration, and the used-equipment secondary market is essentially nonexistent because the technology only achieved broad clinical adoption in the early 2020s. What is publicly verifiable is the system architecture — a capital generator, a peristaltic cooling pump, and a single-use needle electrode per procedure — and that architecture determines where the real cost sits. Procurement officers should expect meaningful capital outlay for the generator/pump bundle and a recurring per-case consumable cost that will drive total cost of ownership far above any one-time hardware purchase. MedSource does not yet have aggregate quote data for this category; this article will be updated as quotes accrue.

---

What the Typical Range Is

No manufacturer list price or GSA schedule entry for the STARmed/TaeWoong EUSRA platform is publicly available as of May 2025. Based on analogous FDA-cleared endoscopic energy generators (e.g., ERBE VIO series, Boston Scientific RFA generators), standalone ablation generator platforms in interventional GI typically range from $25,000–$80,000 for the capital unit. The VIVA Pump (peristaltic cooling system) is sold as a separate capital item. Used-equipment marketplaces such as DOTmed and eBay Medical do not currently list the VIVA Combo RF Generator, confirming the product's nascent U.S. footprint.

The more predictable cost — and the one that dominates over a program's lifetime — is the EUSRA single-use electrode. The EUSRA RF Electrode is a sterile, single-use electrosurgical accessory intended to be used in conjunction with the VIVA Combo RF Generator, comprising an electrode tip, handle, and tubing. Analogous single-use EUS accessories (e.g., FNA needles, EUS-guided stent systems) run $200–$800 per unit; a dedicated RFA electrode with internal cooling carries higher manufacturing complexity and is likely priced toward the upper end of that range or above. Grounding pads are an additional per-case consumable. No verified per-unit electrode price is publicly available. Contact TaeWoong Medical USA or STARmed America directly and require a formal written quote before any capital conversation.

---

What Pushes Price Up — Features, Certifications, Support Tier

FDA clearance status. The only U.S. FDA-cleared device for EUS-RFA is the STARmed EUSRA RF electrode from TaeWoong Medical USA — a single-use 19-gauge RFA needle with an active tip length ranging from 5 mm to 15 mm that connects to their VIVA RF generator. Regulatory clearance on a niche platform typically supports premium pricing; there is no cleared domestic competitor to create downward pressure.

Generator output range. The VIVA Combo RF Generator is designed for both percutaneous ultrasound-guided and endoscopic ultrasound-guided radiofrequency procedures across multiple organ indications, operating at a wide power range from 5–200 Watts suitable for thyroid, biliary, pancreatic, liver, lung, kidney, uterine fibroid, and bone tumors. Multi-specialty configurability commands higher pricing than single-indication generators.

IEC compliance tier. The VIVA Combo RF System is certified to IEC 60601-1, IEC 60601-2-2, and IEC 60601-1-2, and is classified as a Class 1 Type BF medical device. Full IEC 60601 suite compliance is expected for hospital procurement, but verify that your specific jurisdiction's requirements (UL listing for U.S. facilities) are met by the configuration quoted.

Electrode active-tip size selection. The EUSRA endoscopic RF electrode comes in three different active tip lengths — 5 mm, 7 mm, or 10 mm — to accommodate a variety of lesion sizes, with an adjustable deploy length of up to 8 cm. Programs treating a range of lesion diameters will need to stock multiple SKUs, increasing per-procedure consumable inventory complexity.

Training and onboarding. EUS-RFA requires advanced endosonography expertise. Vendor-provided proctored cases and hands-on wet-lab training (often bundled into launch agreements) add implicit costs that inflate the effective acquisition price.

---

What Pushes Price Down — Refurbished, Older Generation, Lease, GPO Contracts

GPO contracting. The EUSRA platform is sufficiently niche that it may not appear on major GPO (Premier, Vizient, HealthTrust) formularies. Confirm directly with your GPO whether a negotiated tier exists; if it does not, use GPO membership as leverage to request most-favored-nation pricing from the distributor.

Capital lease structures. For a low-volume program (fewer than 20–30 EUS-RFA cases/year), a capital lease on the generator/pump bundle — rather than an outright purchase — transfers technology-obsolescence risk to the vendor and preserves capital budget. Monthly operating lease payments for analogous generators run approximately $800–$2,500/month depending on term and included service tier.

Reagent-rental / cost-per-procedure models. Some specialty device distributors offer generator placement at no upfront cost in exchange for a committed per-electrode volume. For centers just launching an EUS-RFA program, this eliminates capital risk but typically yields a higher per-electrode unit price. Model both scenarios with projected case volume over 36–60 months before committing.

Refurbished market. No refurbished EUSRA generators currently appear on established secondary platforms (DOTmed, Bimedis, MedWow as of May 2025). This is not expected to change materially in the next 12–18 months given the device's U.S. market age.

---

Hidden Costs — Install, Training, Calibration, Consumables, Service Contracts

Cooling pump and tubing sets. The VIVA Combo RF System consists of an RF generator, active electrode, grounding pad, and peristaltic pump for electrode cooling; the system is capable of delivering up to 200 W of RF power with software-controlled limits. The VIVA Pump is a separate capital item — confirm whether it is included in the generator quote or priced separately.

Per-procedure consumable stack. Every EUS-RFA case consumes at minimum: one EUSRA electrode (single-use), one grounding pad, and coolant tubing. The EUSRA RF Electrode is a sterile, single-use electrosurgical accessory. Reuse is prohibited. Budget consumable costs per case before launching volume projections.

Therapeutic echoendoscope compatibility. EUS-RFA requires a linear-array therapeutic echoendoscope (e.g., Olympus GF-UCT180, Pentax EG-3270UK). If your endoscopy suite does not already own a compatible linear scope, add $35,000–$60,000 for that capital asset. Scope repair and maintenance contracts run 8–12% of purchase price annually.

Ancillary imaging. Contrast-enhanced harmonic EUS (CH-EUS) is performed at procedure start to better define lesion location, margins, and vascularity, and is repeated during RFA to delineate real-time vascular perfusion and detect residual neoplastic tissue. Ultrasound contrast agent (e.g., Lumason/SonoVue) adds a per-case pharmaceutical cost not typically captured in device budget lines.

Service contracts. Specialty GI energy generators typically carry annual service contracts priced at 8–12% of the capital purchase price. Because the VIVA Combo is manufactured in South Korea, parts availability and response time SLAs should be written explicitly into any contract — particularly for 4-hour or next-business-day on-site response commitments.

Staff credentialing and training. Wet-lab proctoring for EUS-RFA typically requires 2–5 proctored cases per advanced endoscopist. Travel, facility fees, and lost clinical time during training can add $5,000–$15,000 per physician to program launch costs.

---

How to Negotiate — Concrete Tactics

1. Demand a formal itemized quote separating the generator, pump, initial electrode order, grounding pads, installation, training, and service contract. Bundled "system" quotes obscure the per-unit electrode price that drives lifetime cost.
2. Require a volume-price schedule for electrodes. Commit to a minimum annual electrode volume (e.g., 50, 100, 150 units) in exchange for tiered per-unit pricing. Even a 15% reduction in electrode unit price compounds significantly over a 3–5 year program.
3. Benchmark against analogous single-use EUS accessories. 19G FNA needles with similar engineering complexity (e.g., Cook Echotip Ultra, Medtronic EchoTip ProCore) are publicly priced at $250–$450 per unit. Use this as a ceiling anchor in electrode negotiations.
4. Negotiate a trial / evaluation period. Request 5–10 complimentary electrodes for a formal clinical evaluation before signing a volume commitment. This is standard practice for single-use GI consumables.
5. Tie service SLAs to penalties. For a niche platform with limited domestic service infrastructure, require contractual remedies (loaner equipment, credit) for downtime exceeding 48–72 hours.
6. Ask about multi-year electrode agreements. A 2–3 year committed purchase order often unlocks generator placement credits or discounted consumable pricing unavailable on single-year terms.

---

When the Price Feels Off — Red Flags

• A quote that includes only the generator and omits the VIVA Pump. The pump is a separate capital component required for electrode cooling; the VIVA pump features an internal cooling system that circulates saline through the electrode to lower the temperature around the active tip. Any quote that does not itemize the pump separately should be treated as incomplete.
• No per-unit electrode price in writing. Verbal per-unit pricing that disappears at contract signature is a significant red flag. Insist on written exhibit pricing before executing a capital agreement.
• A "cleared for EUS-RFA" claim from a non-EUSRA/STARmed vendor. The only U.S. FDA-cleared device for EUS-RFA is the STARmed EUSRA RF electrode from TaeWoong Medical USA. Any competitor claiming equivalent FDA clearance for pancreatic EUS-RFA should be asked to produce the specific 510(k) clearance number for independent verification on the FDA 510(k) database.
• Unrealistically long lead times on consumables. Given Korean manufacturing origin, ask for explicit lead-time commitments (days from order to delivery) and minimum safety-stock recommendations. A program with 3–4 week lead times on single-use electrodes carries material clinical and operational risk.
• Service contracts with broad "acts of God" or "supply chain" carve-outs. Post-2020 supply chain volatility has made vague exclusions more consequential; require specific response-time guarantees that are not waivable by the vendor due to logistics delays.

---

Sources

1. TaeWoong Medical USA / STARmed America — EUSRA product page, VIVA Combo RF Generator product page, EUSRA brochure (manufacturer technical documentation; no list pricing published). taewoongusa.com / starmed-america.com
2. MDPI Diagnostics (2023) — "A Review on Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of Pancreatic Lesions." Peer-reviewed review covering device specifications, FDA clearance status, and procedural parameters. mdpi.com/2075-4418/13/3/536
3. ManualsLib — STARmed VIVA Combo RF System User Manual — IEC 60601-1/60601-2-2/60601-1-2 certification confirmation, Class 1 Type BF classification, power output specifications. manualslib.com
4. RevMed Connect — STARmed product listing — Component-level breakdown of VIVA Combo RF System (generator, electrode, grounding pad, peristaltic pump). revmedconnect.com

Disclosure: MedSource has not yet collected aggregate quote data for EUS-RFA systems. All capital price ranges cited for analogous devices are based on publicly available secondary market and manufacturer data for comparable GI energy platforms and are intended as order-of-magnitude planning figures only. This article will be updated as verified quote data accrues. Contact MedSource to submit a quote for aggregation.